Literature DB >> 10646889

Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.

M H Black1, A Magklara, C Obiezu, M A Levesque, D J Sutherland, D J Tindall, C Y Young, E R Sauter, E P Diamandis.   

Abstract

The recent demonstration of human glandular kallikrein (hK2) expression in a breast carcinoma cell line has suggested that this putatively prostate-restricted, steroid hormone-regulated protease may also be expressed in breast epithelium in vivo and secreted into the mammary duct system. Given that the only substrate yet identified for hK2 activity is the precursor of prostate-specific antigen (PSA), the expression of which in breast carcinomas may be associated with favourable prognosis, our purpose was to examine the expression pattern of both hK2 and PSA in breast tumour tissues. Cytosolic extracts of 336 primary breast carcinomas prepared for routine oestrogen receptor (ER) and progesterone receptor (PR) analysis, as well as 31 nipple aspirates from six women with non-diseased mammary glands, were assayed for hK2 and PSA using immunofluorometric assays developed by the authors. In the tumour extracts, measurable hK2 and PSA concentrations were detected in 53% and 73% of cases respectively, and were positively correlated to each other (r = 0.59, P = 0.0001). Higher concentrations of PSA and hK2 were found in tumours expressing steroid hormone receptors (P = 0.0001 for PSA and P = 0.0001 for hK2, by Wilcoxon tests for both ER and PR), and both PSA (r = 0.25, P = 0.0001) and hK2 (r = 0.22, P = 0.0001) correlated directly with PR levels. A negative correlation between patient age and PSA (r = -0.12, P = 0.03) was also found. Both proteins were present in nipple aspirate fluid at relatively high concentrations which were positively correlated (r = 0.53, P = 0.002). The molecular weights of the immunoreactive species quantified by the hK2 and PSA assays were established by high-performance liquid chromatography (HPLC) and were consistent with the known molecular weights of hK2 and PSA. Together these data provide the first evidence, to our knowledge, that both malignant breast tissue and normal breast secretion contain measurable quantities of hK2, and that the degree of hK2 expression or secretion is directly proportional to the expression of PSA and steroid hormone receptors. hK2 expression may therefore be a marker of steroid hormone action in breast tissue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646889      PMCID: PMC2363279          DOI: 10.1054/bjoc.1999.0927

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.

Authors:  R A Ferguson; H Yu; M Kalyvas; S Zammit; E P Diamandis
Journal:  Clin Chem       Date:  1996-05       Impact factor: 8.327

2.  Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.

Authors:  M L Hsieh; M C Charlesworth; M Goodmanson; S Zhang; T Seay; G G Klee; D J Tindall; C Y Young
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

3.  Prostate-specific antigen in nipple aspirate.

Authors:  L Foretova; J E Garber; N L Sadowsky; S J Verselis; F P Li
Journal:  Lancet       Date:  1996-06-08       Impact factor: 79.321

4.  Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.

Authors:  A Kumar; S D Mikolajczyk; A S Goel; L S Millar; M S Saedi
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

5.  Nonprostatic sources of prostate-specific antigen.

Authors:  E P Diamandis; H Yu
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

6.  Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

Authors:  T K Takayama; K Fujikawa; E W Davie
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

7.  Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.

Authors:  E R Sauter; M Daly; K Linahan; H Ehya; P F Engstrom; G Bonney; E A Ross; H Yu; E Diamandis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-12       Impact factor: 4.254

8.  Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer.

Authors:  L C Lai; H Erbas; T W Lennard; R T Peaston
Journal:  Int J Cancer       Date:  1996-06-11       Impact factor: 7.396

9.  Kallikrein gene expression in human pituitary tissues.

Authors:  J A Clements; A Mukhtar; K Verity; M Pullar; P McNeill; J Cummins; P J Fuller
Journal:  Clin Endocrinol (Oxf)       Date:  1996-02       Impact factor: 3.478

10.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.

Authors:  N Zarghami; L Grass; E P Diamandis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  3 in total

1.  Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Authors:  Daniel L J Thorek; Philip A Watson; Sang-Gyu Lee; Anson T Ku; Stylianos Bournazos; Katharina Braun; Kwanghee Kim; Kjell Sjöström; Michael G Doran; Urpo Lamminmäki; Elmer Santos; Darren Veach; Mesruh Turkekul; Emily Casey; Jason S Lewis; Diane S Abou; Marise R H van Voss; Peter T Scardino; Sven-Erik Strand; Mary L Alpaugh; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert
Journal:  Sci Transl Med       Date:  2016-11-30       Impact factor: 17.956

2.  Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?

Authors:  Sandra J Roddiger; Heiner Renneberg; Thomas Martin; Ulf W Tunn; Nikolaos Zamboglou; Ralf Kurek
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-12       Impact factor: 4.553

3.  Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Authors:  Daniel L J Thorek; Anson T Ku; Nicholas Mitsiades; Darren Veach; Philip A Watson; Dipti Metha; Sven-Erik Strand; Sai Kiran Sharma; Jason S Lewis; Diane S Abou; Hans G Lilja; Steven M Larson; Michael R McDevitt; David Ulmert
Journal:  Clin Cancer Res       Date:  2018-09-25       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.